Xolair omalizumab for injection instructions for use: indications, subcutaneous dosage, warnings, and administration for moderate-to-severe allergic asthma.
This Chinese package insert provides instructions for Xolair (omalizumab for injection), a 150 mg/vial lyophilized powder supplied with sterile water for injection and intended for subcutaneous use under physician supervision.
It warns of rare allergic reactions after injection, covers moderate-to-severe persistent allergic asthma in adults and adolescents aged 12 and older, and provides IgE- and weight-based dosing tables, preparation steps, injection sites, and adverse reaction information. This manual is written in Chinese.
| Specification | 150 mg/vial |
|---|---|
| Reconstituted concentration | 125 mg/mL |
| Molecular weight | 150,000 daltons |
It is used for moderate-to-severe persistent allergic asthma.
It is given by subcutaneous injection only, in the upper arm or thigh.
It should be administered by healthcare professionals.
No, it must not be used if solid particles are present.